Johan Henely
Executive Director
Ablynx
Belgium
Biography
Johan assumes responsibility for all Ablynx’s commercial activities and late stage project management. He has more than 20 years of experience in global biopharmaceutical sales, marketing and business development at GlaxoSmithKline (GSK), Servier and Wyeth. Prior to joining Ablynx, Johan was Executive Director, Global Commercial Lead, Cancer Immunotherapeutics, at GSK, where he headed the global commercial teams and was responsible for the development and implementation of the launch strategy for GSK’s cancer immunotherapeutics portfolio. Prior to that, Johan led and launched the successful global commercial and marketing efforts for three of GSK’s paediatric vaccines, Rotarix®, Priorix® and Varilrix®, which together achieved sales of more than €1.5 billion. He has experience in a wide range of therapeutic fields and regions, having worked and lived in Europe, Latin-America, Asia and in the USA. Johan holds degrees in pharmacy (KUL), economics (VLEKHO) and management (ULB, Solvay Business School and the Stockholm School of Economics). Johan has been guest speaker at congresses and universities throughout Europe on Clinical R&D and Marketing, and is currently lecturer in marketing at the Université Libre de Bruxelles (Pharmed). In addition to his duties as CCO of Ablynx, he is Director and Member of the Board of FlandersBio.
Research Interest
Johan assumes responsibility for all Ablynx’s commercial activities and late stage project management. He has more than 20 years of experience in global biopharmaceutical sales, marketing and business development at GlaxoSmithKline (GSK), Servier and Wyeth. Prior to joining Ablynx, Johan was Executive Director, Global Commercial Lead, Cancer Immunotherapeutics, at GSK, where he headed the global commercial teams and was responsible for the development and implementation of the launch strategy for GSK’s cancer immunotherapeutics portfolio. Prior to that, Johan led and launched the successful global commercial and marketing efforts for three of GSK’s paediatric vaccines, Rotarix®, Priorix® and Varilrix®, which together achieved sales of more than €1.5 billion. He has experience in a wide range of therapeutic fields and regions, having worked and lived in Europe, Latin-America, Asia and in the USA. Johan holds degrees in pharmacy (KUL), economics (VLEKHO) and management (ULB, Solvay Business School and the Stockholm School of Economics). Johan has been guest speaker at congresses and universities throughout Europe on Clinical R&D and Marketing, and is currently lecturer in marketing at the Université Libre de Bruxelles (Pharmed). In addition to his duties as CCO of Ablynx, he is Director and Member of the Board of FlandersBio.
